CAR-T Therapies Not Cost-Effective for Diffuse Large B-Cell Lymphoma

MONDAY, Dec. 4, 2023-- For patients with diffuse large B-cell lymphoma (DLBCL), the chimeric antigen receptor T-cell therapies (CAR-T) axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel) are not cost-effective, according to a...